HighVista Strategies LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

HighVista Strategies LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent filing with the SEC. The firm acquired 2,602 shares of the biopharmaceutical company’s stock, valued at approximately $632,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital International Investors increased its position in Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock worth $686,641,000 after purchasing an additional 488,814 shares during the period. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares during the last quarter. Capital Research Global Investors raised its stake in shares of Alnylam Pharmaceuticals by 7.3% during the first quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after buying an additional 214,908 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after acquiring an additional 201,784 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth $18,886,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $273.88 on Monday. The company has a market cap of $34.64 billion, a price-to-earnings ratio of -102.19 and a beta of 0.38. The firm has a 50-day moving average of $260.11 and a 200-day moving average of $199.42. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. The business’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same period last year, the company posted ($2.21) earnings per share. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Insider Activity

In related news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now directly owns 136 shares in the company, valued at $35,632. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 2,103 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $485,771.97. Following the transaction, the chief marketing officer now owns 15,609 shares in the company, valued at $3,605,522.91. The disclosure for this sale can be found here. In the last 90 days, insiders sold 70,698 shares of company stock valued at $18,497,434. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. JPMorgan Chase & Co. boosted their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Evercore ISI upped their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, June 25th. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $279.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.